Nivolumab or Ipilimumab in Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Ran

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 03 Mar 2026. The item focuses on Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial. Review the original article for the full source wording and details.